Pfizer, Seagen kick off antitrust review of $43B merger. Will FTC get on board?

Pfizer and Seagen on Friday submitted paperwork for their proposed $43 billion merger to the Federal Trade Commission and the Department of Justice, Seagen said in a filing Monday. Pfizer plans to acquire Seagen for $229 per share in cash.